Halopiperidines for imaging of monoamine transporters

Information

  • Research Project
  • 6645217
  • ApplicationId
    6645217
  • Core Project Number
    R43NS046109
  • Full Project Number
    1R43NS046109-01
  • Serial Number
    46109
  • FOA Number
  • Sub Project Id
  • Project Start Date
    7/1/2003 - 20 years ago
  • Project End Date
    6/30/2004 - 19 years ago
  • Program Officer Name
    GRABB, MARGARET C.
  • Budget Start Date
    7/1/2003 - 20 years ago
  • Budget End Date
    6/30/2004 - 19 years ago
  • Fiscal Year
    2003
  • Support Year
    1
  • Suffix
  • Award Notice Date
    5/26/2003 - 21 years ago

Halopiperidines for imaging of monoamine transporters

[unreadable] DESCRIPTION (provided by applicant): The monoamine transporters are important targets for therapy, diagnosis and monitoring of a number of CNS disease states. It is expected that imaging agents that exhibit high affinity and selectivity for the dopamine transporter (DAT) would fulfill a number of unmet needs including use for Parkinson's disease (PD), ADD/ADHD, depression and cocaine abuse. Additionally, imaging agents that exhibit high affinity and selectivity for either the serotonin or norepinephrine transporters would similarly be of utility for the diagnosis and monitoring of depressive syndromes and related disorders. While, many studies have reported the design of radioligands for the DAT no agents have been disclosed that exhibit favorable imaging properties that are required for widespread utilization. Fewer reports are available on specific radioligands for the serotonin (5-HTT) and norepinephrine (NET) transporters. Herein, we propose the rational design and synthesis a series of halogenated piperidines as potential radio-tracers for imaging of the monoamine transporters utilizing PET and SPECT. These studies utilize our versatile and efficient piperidine pharmacophore for the facile preparation of highly selective monoamine transporter ligands exploiting the divergent structure activity relationships for the enantiomers/isomers of the piperidine. In this manner it is anticipated that this work will result in the identification of new radiopharmaceuticals that can be labeled with positron emitting elements for PET, or single photon emitting elements for SPECT. These radiopharmaceuticals would be of wide spread use for both the diagnosis of CNS disorders and the monitoring of therapeutic interventions. [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
  • Activity
    R43
  • Administering IC
    NS
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    190643
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    853
  • Ed Inst. Type
  • Funding ICs
    NINDS:190643\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    MOLECULAR INSIGHT PHARMACEUTICALS, INC.
  • Organization Department
  • Organization DUNS
    076298459
  • Organization City
    CAMBRIDGE
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    02142
  • Organization District
    UNITED STATES